Celgene aims to block a generic of blood cancer treatment Revlimid

08/25/2010 | Wall Street Journal, The

Celgene plans to "enforce its extensive intellectual property rights" on multiple myeloma drug Revlimid after an unnamed drugmaker filed for FDA approval of a generic version. The treatment is covered by 12 patents, with expiration as far out as 2026. Celgene has not received formal notice of the generic challenge.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
Actuary
NTA Life
Addison, TX
Vice President - Government Products
Health Alliance Plan
Detroit, MI